Pfizer Licenses Commercial Rights to Biocon’s Biosimilar Insulin Products
By Heather Cartwright
Pharma Deals Review: Vol 2010 Issue 9 (Table of Contents)
Published: 2 Nov-2010
DOI: 10.3833/pdr.v2010.i9.1396 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Aiming to secure a firm foothold in the biosimilars market, Pfizer has licensed exclusive global commercialisation rights to Biocon’s versions of insulin and insulin analogue products, with some geographical exceptions...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS